Clinical trials: Emphysema
Emphysema
EASE Trial: Exhale Airway Stents for Emphysema
This is an international clinical research study evaluating the safety and effectiveness of a new procedure called airway bypass.
- Trial name
- EASE (NCT00391612)
- Testing
- Exhale® Drug-Eluting Stent
- Where
- 37 sites in United States, Australia and 8 more
- Volunteers
- 450 people
- Sponsor
- Broncus Technologies
Emphysema, Alpha 1-proteinase Inhibitor Deficiency
Extension Study of Zemaira® i.v. Administration in Subjects With Emphysema Due to alpha1-proteinase Inhibitor Deficiency.
This study is a continuation of the placebo-controlled study CE1226_4001 (NCT00261833) to evaluate the efficacy and safety of Zemaira® intravenous (i.v).
- Trial name
- NCT00670007
- Testing
- Alpha1- proteinase inhibitor [human]
- Where
- 21 sites in Australia, Canada and 9 more
- Volunteers
- 140 people
- Sponsor
- CSL Behring
Alpha 1-Antitrypsin Deficiency
Study of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)
The purpose of this study is to evaluate the the safety and efficacy of the investigational product, fazirsiran (TAK-999, ARO-AAT), administered subcutaneously to patients with alpha-1 antitrypsin deficiency associated liver…
- Trial name
- NCT03946449
- Testing
- ARO-AAT
- Where
- 4 sites in Austria, Germany and 1 more
- Volunteers
- 16 people
- Sponsor
- Arrowhead Pharmaceuticals
Pulmonary Emphysema
Post Market Registry Study of the AeriSeal System
Obtain and analyze medical record data on patients with advanced emphysema who receive treatment with the AeriSeal System to better understand safety and effectiveness in the post-market setting; Provide participating physicians…
- Trial name
- NCT01520064
- Where
- 12 sites in Germany, Israel
- Volunteers
- 25 people
- Sponsor
- Aeris Therapeutics
Pulmonary Emphysema, Chronic Obstructive Pulmonary Disease
Israeli Biologic Lung Volume Reduction (BLVR) Phase 1 Emphysema Study
The purpose of this study is to evaluate the safety and efficacy of the Biologic Lung Volume Reduction System (BLVR) for patients with advanced emphysema refractory to medical therapy.
- Trial name
- NCT00517998
- Testing
- Biologic Lung Volume Reduction (BLVR) - 10 mL Hydrogel
- Where
- Israel
- Volunteers
- 16 people
- Sponsor
- Aeris Therapeutics
Emphysema or COPD
Zephyr Etude Post-Inscription (French Registry)
The objective of this Registry is to provide ongoing safety and effectiveness assessment of the Zephyr Valve treatment of adult patients with Chronic Obstructive Pulmonary Disease (COPD) Grade III and Grade IV in order to support…
- Trial name
- NCT04517916
- Testing
- Zephyr Valve
- Where
- 12 sites in France
- Volunteers
- 155 people
- Sponsor
- Pulmonx Corporation
Emphysema
Pulmonx Endobronchial Valves Used in Treatment of Emphysema (LIBERATE Study)
The purpose of this research is to study an investigational medical device that is designed to produce lung volume reduction in diseased areas of the lungs in patients with severe emphysema.
- Trial name
- LIBERATE (NCT01796392)
- Testing
- EBV, Optimal Medical Management
- Where
- 23 sites in United States, Brazil and 2 more
- Volunteers
- 190 people
- Sponsor
- Pulmonx Corporation
Chronic Obstructive Pulmonary Disease
Study of the Effect of the ROX AC1 on Exercise Capacity and Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients
To demonstrate the efficacy of ROX AC1 (with respect to exercise capacity and quality of life) in patients with COPD.
- Trial name
- NCT00832611
- Testing
- Arteriovenous Fistula (ROX AC1)
- Where
- Germany
- Volunteers
- 46 people
- Sponsor
- ROX Medical, Inc.
Pulmonary Hypertension, Interstitial Lung Disease
Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE
This was a multicenter, randomized (1:1 inhaled treprostinil: placebo), double-blinded, placebo-controlled trial to evaluate the safety and efficacy of inhaled treprostinil in subjects with pre-capillary pulmonary hypertension…
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease, Combined Pulmonary Fibrosis and Emphysema
- Trial name
- NCT02630316
- Testing
- Inhaled Treprostinil
- Where
- 97 sites in United States, Puerto Rico
- Volunteers
- 326 people
- Sponsor
- United Therapeutics
Lung Disease
Use of Autologous, Adult Adipose-Derived Stem/Stromal Cells In Chronic Lung Disorders
Chronic Obstructive Pulmonary Disease (COPD) is a lung-related disorder that is characterized by long-term, often progressive state of poor airflow.
- Trial name
- ADcSVF-COPD (NCT02946658)
- Testing
- lipoaspiration, ADcSVF, Normal Saline IV
- Where
- 2 sites in United States, Honduras
- Volunteers
- 100 people
- Sponsor
- Healeon Medical Inc
Pulmonary Emphysema
Collateral Ventilation Effects on Response to AeriSeal System Treatment in Upper Lobe Predominant Emphysema
This study will evaluate the effects of baseline collateral ventilation status on outcomes following treatment with AeriSeal System in patients with advanced upper-lobe predominant heterogenous emphysema.
- Trial name
- CV+/- (NCT01520740)
- Testing
- Emphysematous Lung Sealant
- Where
- 13 sites in Germany, Israel
- Volunteers
- 100 people
- Sponsor
- Aeris Therapeutics
Emphysema, Chronic Obstructive Pulmonary Disease (COPD)
AeriSeal System for Lung Volume Reduction
The purpose of this study is to evaluate the safety and efficacy of AeriSeal treatment in patients with advanced emphysema.
- Conditions
- Emphysema, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Emphysema, Lung Diseases
- Trial name
- NCT01051258
- Testing
- AeriSeal System
- Where
- 8 sites in Austria, France and 2 more
- Volunteers
- 55 people
- Sponsor
- Aeris Therapeutics
Emphysema, Chronic Obstructive Pulmonary Disease
Bronchoscopic Thermal Vapor Ablation (BTVA) for Lung Volume Reduction
To establish and confirm the safety and clinical utility of BTVA applied unilaterally for lung volume reduction in patients with upper lobe predominate heterogeneous severe emphysema.
- Trial name
- BTVA (NCT01102712)
- Testing
- BTVA System
- Where
- 10 sites in Australia, Austria and 2 more
- Volunteers
- 34 people
- Sponsor
- Uptake Medical Corp
Chronic Obstructive Pulmonary Disease
Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
The purpose of this study is to assess the long-term safety and tolerability of inhaled aclidinium bromide/formoterol in patients with moderate to severe, stable chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT01437540
- Testing
- Aclidinium Bromide/Formoterol Fumarate, Formoterol Fumarate
- Where
- 137 sites in United States
- Volunteers
- 590 people
- Sponsor
- AstraZeneca
Alpha 1-Antitrypsin Deficiency
A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)
This is a Phase 1/2, multicenter, open-label study conducted in 3 parts (Part A, Part B, and Part C) to evaluate the safety, tolerability, PK/PD, and efficacy of BEAM-302 in adult patients with AATD-associated lung disease and/or…
- Trial name
- NCT06389877
- Testing
- BEAM-302
- Where
- 12 sites in United States, Australia and 4 more
- Volunteers
- 192 people
- Sponsor
- Beam Therapeutics Inc.
Emphysema
Evaluation of Physiologic Parameters to Study the Mechanism of Action of the Lung Volume Reduction Coil in Subjects With Homogeneous Emphysema
The PneumRx Lung Volume Reduction Coil (LVRC) has been shown to effectively improve quality of life, exercise capacity, and static lung volumes, in patients with emphysema.
- Trial name
- NCT01421082
- Testing
- Lung Volume Reduction Coil (LVRC) (PneumRx, Inc.)
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Boston Scientific Corporation
Advanced Upper Lobe Predominant Emphysema
Phase 3 Study of the Biologic Lung Volume Reduction (BLVR) System in Advanced Upper Lobe Predominant (ULP) Emphysema
The purpose of the study is to evaluate the efficacy and safety of the 20 mL BLVR System in treating patients with advanced upper lobe predominant emphysema.
- Trial name
- NCT00716053
- Testing
- BLVR
- Volunteers
- 225 people
- Sponsor
- Aeris Therapeutics
Alpha 1-Antitrypsin Deficiency
A Study of Belcesiran in Patients With AATLD
This is a multiple dose, randomized, placebo-controlled, double-blind study of belcesiran to evaluate the safety, tolerability, PK, and PD in adult patients with PiZZ AATD-associated liver disease (AATLD).
- Trial name
- ESTRELLA (NCT04764448)
- Testing
- Belcesiran
- Where
- 23 sites in United States, Australia and 12 more
- Volunteers
- 16 people
- Sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Emphysema, Pulmonary Disease, Chronic Obstructive
A Multicenter, Prospective Trial of the IAB in Adults Suffering From COPD/Emphysema
The Pulmair Implantable Artificial Bronchus (IAB) is a device intended for implantation into the diseased bronchi of emphysema patients.
- Trial name
- IAB-1 (NCT05087641)
- Testing
- IAB System
- Where
- 3 sites in Brazil, Germany and 1 more
- Volunteers
- 20 people
- Sponsor
- Pulmair Medical, Inc.
Alpha1-Antitrypsin Deficiency
Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)
The liver produces a protein called alpha-1 antitrypsin (AAT). AAT is normally released into the bloodstream. In some people, the liver makes an abnormal version of the AAT protein, called Z-AAT.
- Trial name
- NCT06165341
- Testing
- Fazirsiran Injection
- Where
- 41 sites in United States, Austria and 11 more
- Volunteers
- 50 people
- Sponsor
- Takeda